Elekta (EKTA-B.ST) Stock Analysis & AI Equity Report
Elekta (EKTA-B.ST) overview
Elekta (EKTA-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Elekta reported revenue of SEK 18,016m and operating profit of SEK 890m; the year-end share price was 49.00 SEK and market capitalisation was SEK 18,722m. Elekta is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Elekta's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Elekta
Elekta develops and sells precision radiation therapy systems, radiosurgery platforms and oncology software used in cancer care. Its portfolio includes image-guided and adaptive radiotherapy, treatment planning and workflow tools, and Gamma Knife systems for stereotactic neurosurgery. The company serves hospitals and clinics worldwide through equipment, software, service and support.
Generate the Elekta report
Elekta is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Elekta and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.